The association of a higher risk for moderate cognitive impairment (BSID <85) after anti-VEGF treatment was present with the use of adjusted data (GA, sex, severe IVH or white matter injury, BPD, surgical NEC, sepsis, maternal education, and SNAP II score), which were reported in only two studies (58, 63). The gene discussed is VEGFA; the disease is Sepsis.